Smarter Cancer Care
In collaboration with thousands of physicians around the world, over one million patients improved their outcomes with the Oncotype IQ portfolio of genomic tests.
See What's New

To everyone on the front lines of patient care during this time,


THANK YOU.


We are here to support you whenever you need us.


ASCO20 Virtual Scientific Program

Join us May 29-31, 2020
See new data for the Oncotype DX Breast Recurrence Score test and how it changes treatment decisions for patients with early-stage breast cancer

American Society of Breast Surgeons (ASBrS) 21st Annual Meeting

Join us May 28, 2020 for a virtual non-CME educational symposium
Topic: Less is More: De-escalation of Local and Systemic Therapy with the Breast Recurrence Score® Test


Exact Sciences' Response to COVID-19

We want to assure you that our Oncotype DX tests remain readily available and that our laboratory continues to operate.
Our patient-critical work teams continue to operate, following all safety procedures and practices.

Real People.
Real Results.
When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
Healthcare Savings
How much do ineffective cancer treatments cost the healthcare system? In the US alone, Oncotype IQ tests have saved more than $3.5 billion.
Practice Tools

The Eighth Edition AJCC Staging Manual is now effect, and it has changed staging for T1-2 N0 M0 breast cancer patients.

Latest TAILORx Data
The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.